These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 2884807)

  • 41. [Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate].
    Viala A; Aymard N; Leyris A; Caroli F
    Therapie; 1996; 51(1):19-25. PubMed ID: 8762216
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Movement disorders in patients treated with long-acting injectable antipsychotic drugs.
    Bransgrove LL; Kelly MW
    Am J Hosp Pharm; 1994 Apr; 51(7):895-9. PubMed ID: 7912473
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Haloperidol decanoate (Janssen) in the treatment of sexual deviations.
    Zbytovský J
    Cesk Psychiatr; 1993 Jan; 89(1):15-7. PubMed ID: 8099535
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence.
    Vasavan Nair NP; Suranyi-Cadotte B; Schwartz G; Thavundayil JX; Achim A; Lizondo E; Nayak R
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):30S-37S. PubMed ID: 3514689
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation.
    Bieniek SA; Ownby RL; Penalver A; Dominguez RA
    Pharmacotherapy; 1998; 18(1):57-62. PubMed ID: 9469682
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Atypical antipsychotic medications in the psychiatric emergency service.
    Currier GW
    J Clin Psychiatry; 2000; 61 Suppl 14():21-6. PubMed ID: 11154013
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
    Cookson JC; Kennedy NM; Gribbon D
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rational antipsychotic polypharmacy.
    Kennedy NB; Procyshyn RM
    Can J Clin Pharmacol; 2000; 7(3):155-9. PubMed ID: 11044761
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of route of administration on haloperidol plasma levels in psychotic patients.
    Bianchetti G; Zarifian E; Poirier-Littre MF; Morselli PL; Deniker P
    Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):324-7. PubMed ID: 7429678
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
    Corripio I; Catafau AM; Perez V; Puigdemont D; Mena E; Aguilar Y; Carrió I; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):91-6. PubMed ID: 15610950
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Administration of high dose haloperidol in a patient refractory to treatment with traditional and atypical neuroleptics].
    Stip E; Bruneau MA
    Encephale; 1996; 22(4):298-300. PubMed ID: 9035986
    [No Abstract]   [Full Text] [Related]  

  • 52. D2-dopamine-receptor occupancy during treatment with haloperidol decanoate.
    Scherer J; Tatsch K; Albus M; Schwarz J; Mager T; Oertel WH
    Eur Arch Psychiatry Clin Neurosci; 1997; 247(2):104-6. PubMed ID: 9177957
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring].
    Balant-Gorgia AE; Eisele R; Garrone G
    Schweiz Med Wochenschr; 1985 Jan; 115(1):14-8. PubMed ID: 2857499
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double blind research].
    Bures E; Pöldinger W
    Int Pharmacopsychiatry; 1978; 13 Suppl 1():45-52. PubMed ID: 35479
    [No Abstract]   [Full Text] [Related]  

  • 55. A six-month follow-up of refractory chronic psychotics treated with Haldol-AID.
    Wouters J
    Acta Psychiatr Belg; 1978; 78(2):399-406. PubMed ID: 354327
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacology and mechanism of action of existing and new neuroleptics.
    Niemegeers CJ
    Acta Psiquiatr Psicol Am Lat; 1990; 36(1-2):26-36. PubMed ID: 1981439
    [No Abstract]   [Full Text] [Related]  

  • 57. [Effective management of the acute psychotic patient: stabilization and maintenance with haloperidol].
    Garfinkel PE
    Acta Psiquiatr Psicol Am Lat; 1978 Dec; 24(4):297-301. PubMed ID: 36735
    [No Abstract]   [Full Text] [Related]  

  • 58. Haloperidol decanoate in the treatment of schizophrenia.
    Zapletálek M; Zbytovský J
    Act Nerv Super (Praha); 1989 Apr; 31(1):39-41. PubMed ID: 2571224
    [No Abstract]   [Full Text] [Related]  

  • 59. Outpatient titration with intramuscular haloperidol as an alternative to psychiatric hospitalization.
    Ingall MA; Farber BL; Kuppe JV; Silveira AP
    R I Med J (1976); 1979 Nov; 62(11):437-42. PubMed ID: 293841
    [No Abstract]   [Full Text] [Related]  

  • 60. [7 years of experience with delayed action neuroleptics].
    Noguera Hosta R; Rendueles de Olmedo G
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1978; 6(3):293-8. PubMed ID: 31066
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.